| Identification | Back Directory | [Name]
Rolapitant | [CAS]
552292-08-7 | [Synonyms]
SCH619734
Rolapitant
Rolapitant-d4
Rolapitant HCl
Rolapitant USP/EP/BP
Rolapitant(sch619734)
rolapitant,914462-92-3
(5S,8S)-8-({(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
(5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
1,7-Diazaspiro[4.5]decan-2-one,8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-,(5S,8S)-
(5S,8S)-8-[[[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]oxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
(5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one hydrochloride. | [EINECS(EC#)]
812-147-5 | [Molecular Formula]
C25H26F6N2O2 | [MDL Number]
MFCD23105917 | [MOL File]
552292-08-7.mol | [Molecular Weight]
500.48 |
| Chemical Properties | Back Directory | [Boiling point ]
523.5±50.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMF:PBS(pH7.2) (1:2): 0.33 mg/ml; DMSO: 16 mg/ml; Ethanol: 3 mg/ml | [form ]
Powder | [pka]
15.88±0.40(Predicted) | [color ]
White to off-white | [InChIKey]
FIVSJYGQAIEMOC-ZGNKEGEESA-N | [SMILES]
N1[C@@]2(CC[C@@](CO[C@@H](C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C)(C3=CC=CC=C3)NC2)CCC1=O |
| Hazard Information | Back Directory | [Description]
Rolapitant [5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl] ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a highaffinity NK1 receptor antagonist recently approved under the name Varubi as a treatment for nausea and vomiting caused by chemotherapy by the U.S. Food and Drug Administration (FDA). Rolapitant is metabolized in vivo primarily by CYP3A4 to form the major metabolite M19.[3] | [Uses]
Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model[1][2]. | [Definition]
ChEBI: An azaspiro compound that is 1,7-diazaspiro[4.5]decan-2-one carrying additional phenyl and 1-{[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl substituents at position 8. Used (in the form of the hydrochloride hydrate) for the prevention of delayed nausea and
vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. | [Synthesis]
At 50 ℃ and 250 rpm, rolapitant, polyethylene glycol 15-hydroxystearate, refined soybean oil and medium-chain triglyceride were heated and stirred for 25 minutes to produce the oil phase; then phosphoric acid, sodium chloride and Porloxam 188 with water f | [in vivo]
Rolapitant (0.03-1 mg/kg for PO, 0.3-1 mg/kg for IV; single dosage) attenuates the GR-73632-induced foot-tapping response in Mongolian Gerbils[1].
Rolapitant (0.03-1 mg/kg; PO; single dosage; observed for 72 h) blocks acute emesis induced by both apomorphine and cisplatin in ferrets[1]. | Animal Model: | Female Mongolian Gerbils (30-60 g; anesthetized by inhalation of an oxygen:isofluorane mixture after 4 h PO or immediately after IV, then injected with 5 μl of 3 pmol solution of GR-73632 via ICV)[1] | | Dosage: | 0.03, 0.1, 0.3 and 1 mg/kg for PO, 0.3 and 1 mg/kg for IV | | Administration: | PO or IV, single dosage | | Result: | Attenuated dose-dependently the GR-73632-induced foot-tapping response when administered PO 4 h before testing, with an ID90 of 0.3 mg/kg, and the inhibition in foot tapping for at least 24 h.
Blocked dose-dependently the foot tapping induced by GR-73632 when administered IV, with complete blockade observed at 1 mg/kg. |
| Animal Model: | Ferrets (treated with subcutaneous administration of 0.125 mg/kg apomorphine or intraperitoneal administration of 10 mg/kg cisplatin)[1] | | Dosage: | 0.03, 0.1, 0.3 and 1 mg/kg | | Administration: | PO; single dosage; observed for 72 h | | Result: | Blocked dose-dependently acute emesis induced by both apomorphine and cisplatin in ferrets.
Produced a robust decrease in retches and vomits in ferrets that was maintained throughout the 72 h observation period. |
| [IC 50]
human NK1: 0.66 nM (Ki); gerbil NK1: 0.13 nM (Ki); guinea pig NK1: 0.72 nM (Ki); monkey NK1: 2.5 nM (Ki); rabbit NK1: 31.7 nM (Ki); rat NK1: 78.6 nM (Ki); mouse NK1: 60.4 nM (Ki) | [storage]
Store at -20°C | [References]
[1] Duffy RA, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokininNK1 receptor antagonist with centrally-mediated antiemetic effects inferrets. Pharmacol Biochem Behav. 2012 Jul;102(1):95-100. DOI:10.1016/j.pbb.2012.03.021
[2] Rapoport B, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015 Nov;23(11):3281-8. DOI:10.1007/s00520-015-2738-1 |
|
| Company Name: |
Wuhan Topule Gold
|
| Telephone: |
+86-02787215551 19945035818 |
| Website: |
http://www.topule.com/ |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|